Drug Profile
Suramin sodium - Bayer
Alternative Names: Antrypol; Bayer 205; CI 1003; Germanin; Metaret; Moranyl; Suramin; Suramin hexasodiumLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Bayer
- Developer Austrian Academy of Sciences; Bayer; National Cancer Institute (USA); Optimum Therapeutics; Pfizer; The First Affiliated Hospital of Zhengzhou University; University of California, San Diego; University of Wisconsin-Madison
- Class Antiprotozoals; Behavioural disorder therapies; Naphthalenesulfonates
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Intercellular signalling peptide and protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Enterovirus A infections
- Discontinued Atherosclerosis; Bladder cancer; Breast cancer; Cancer pain; HIV infections; Non-small cell lung cancer; Pervasive child development disorders; Prostate cancer; Vascular restenosis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Enterovirus A infections(In volunteers) in China (IV)
- 08 Apr 2021 Discontinued - Phase-I/II for Pervasive child development disorders in USA (IV) (NCT02508259)
- 08 Apr 2021 Discontinued - Phase-II for Non-small cell lung cancer in USA (IV) (NCT01038752)